Endometrial cancer

• Alternative Names

  Endometrial/uterine adenocarcinoma; Uterine cancer; Adenocarcinoma of the endometrium/uterus; Cancer - uterine; Cancer - endometrial; Uterine corpus cancer

• Causes, incidence, and risk factors

  Endometrial cancer is the most common type of uterine cancer. Although the exact cause of endometrial cancer is unknown, increased levels of estrogen appear to play a role. Estrogen helps stimulate the buildup of the lining of the uterus. Studies have shown that high levels of estrogen in animals result in excessive endometrial growth and cancer.

  Most cases of endometrial cancer occur between the ages of 60 and 70 years, but a few cases may occur before age 40.

  The following increase your risk of endometrial cancer:

  • Diabetes
  • Estrogen replacement therapy without the use of progesterone
  • History of endometrial polyps or other benign growths of the uterine lining
  • Infertility (inability to become pregnant)
  • Tamoxifen, a drug for breast cancer treatment
  • Never being pregnant
  • Obesity
  • Starting menstruation at an early age (before age 12)
  • Starting menopause after age 50

  Associated conditions include the following:

  • Colon or breast cancer
  • Hypertension
  • Polycystic ovarian disease
• Symptoms
  • Abnormal uterine bleeding, abnormal menstrual periods
    • Bleeding between normal periods before menopause
    • Vaginal bleeding or spotting after menopause
  • Extremely long, heavy, or frequent episodes of vaginal bleeding after age 40
  • Lower abdominal pain or pelvic cramping
  • Thin white or clear vaginal discharge after menopause
• Signs and tests

  A pelvic examination is frequently normal, especially in the early stages of disease. Changes in the size, shape, or feel of the uterus or surrounding structures may be seen when the disease is more advanced.

  Tests that may be done include:

  • Endometrial aspiration or biopsy
  • Dilation and curettage (D and C)
  • Pap smear (may raise a suspicion for endometrial cancer, but does not diagnose it)

  If cancer is found, other tests may be done to determine how widespread the cancer is and whether it has spread to other parts of the body. This is called staging.

  Stages of endometrial cancer:

  1. The cancer is only in the uterus.
  2. The cancer is in the uterus and cervix.
  3. The cancer has spread outside of the uterus but not beyond the true pelvis area. Cancer may involve the lymph nodes in the pelvis or near the aorta (the major artery in the abdomen).
  4. The cancer has spread to the inner surface of the bowel, bladder, abdomen, or other organs.

  Cancer is also described as Grade 1, 2, or 3. Grade 1 is the least aggressive, and grade 3 is the most aggressive.

• Treatment

  Treatment options involve surgery, radiation therapy, and chemotherapy.

  A hysterectomy may be performed in women with the early stage 1 disease. Removal of the tubes and ovaries (bilateral salpingo-oophorectomy) is also usually recommended.

  Abdominal hysterectomy is recommended over vaginal hysterectomy. This type of hysterectomy allows the surgeon to look inside the abdominal area and remove tissue for a biopsy.

  Surgery combined with radiation therapy is often used to treat women with stage 1 disease that has a high chance of returning, has spread to the lymph nodes, or is a grade 2 or 3. It is also used to treat women with stage 2 disease.

  Chemotherapy may be considered in some cases, especially for those with stage 3 and 4 disease.

• Support Groups

  The stress of illness may be eased by joining a support group whose members share common experiences and problems. See cancer - support group.

• Expectations (prognosis)

  Endometrial cancer is usually diagnosed at an early stage. The 1-year survival rate is about 92%.

  The 5-year survival rate for endometrial cancer that has not spread is 95%. If the cancer has spread to distant organs, the 5-year survival rate drops to 23%.

• Complications

  Complications may include anemia due to blood loss. A perforation (hole) of the uterus may occur during a D and C or endometrial biopsy.

  There can also be complications from hysterectomy, radiation, and chemotherapy.

• Calling your health care provider

  Call for an appointment with your health care provider if you have abnormal vaginal bleeding or any other symptoms of endometrial cancer. This is particularly important if you have any associated risk factors or if you have not had routine pelvic exams.

  Any of the following symptoms should be reported immediately to the doctor:

  • Bleeding or spotting after intercourse or douching
  • Bleeding lasting longer than 7 days
  • Periods that occur every 21 days or more
  • Bleeding or spotting after 6 months or more of no bleeding at all
• Prevention

  All women should have regular pelvic exams beginning at the onset of sexual activity (or at the age of 21 if not sexually active) to help detect signs of infection of abnormal development. Women should have Pap smears beginning 3 years after becoming sexually active.

  Women with any risk factors for endometrial cancer should be followed more closely by their doctors. Frequent pelvic examinations and screening tests such as a Pap smear and endometrial biopsy should be considered.

  Women who are taking estrogen replacement therapy should have regular pelvic examinations and Pap smears.

• References

  American Cancer Society. Cancer Facts and Figures 2008. Atlanta, Ga: American Cancer Society; 2008.

  Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKena WG. Clinical Oncology. 3rd ed. Orlando, Fl: Churchill Livingstone; 2004:2273-2304.

  Katz VL, Lentz GM, Lobo RA, Gershenson DM. Comprehensive Gynecology. 5th ed. Philadelphia, Pa: Mosby Elsevier; 2007.

  Hernandez E, American College of Obstericians and Gynecologists. ACOG practice bulletin number 65: management of endometrial cancer. Obstet Gynecol. 2006;107(4):952.

Review Date: 5/2/2008

Reviewed By: David C. Dugdale, III, MD, Professor of Medicine, Division of General Medicine, Department of Medicine, University of Washington School of Medicine; and Susan Storck, MD, FACOG, Clinical Teaching Faculty, Department of Obstetrics and Gynecology, University of Washington School of Medicine; Chief, Eastside Department of Obstetrics and Gynecology, Group Health Cooperative of Puget Sound, Redmond, Washington. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.